RxDoctor Payments Data

Jonathon Lavalley, PA

Physician Assistant · Grants, NMNPI 1871915702

Payments from drug & device makers

$950in general payments, 2019–2025

Across 52 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$221
  • Boehringer Ingelheim$172
  • Abbott$145
  • Novartis$136
  • Lilly USA, LLC$88
  • Merck$66
  • plus $121 from 4 others

What the payments were for

  • Food & beverage$89694%
  • Education$546%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$950 in reported general payments places this provider in the 80th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Medicare billing

Part B allowed, 2024
$1,932
Medicare patients
136
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide255$316,979
MounjaroTirzepatide186$220,759
XareltoRivaroxaban91$112,564
Tresiba Flextouch U-200Insulin Degludec110$99,024
FarxigaDapagliflozin Propanediol62$80,775
EliquisApixaban49$55,017
JardianceEmpagliflozin36$38,706
RybelsusSemaglutide16$32,164
Xigduo XrDapaglifloz Propaned/Metformin27$24,058
Spiriva RespimatTiotropium Bromide35$23,946
EntrestoSacubitril/Valsartan20$14,748
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$11,932
Fiasp FlextouchInsulin Aspart (Niacinamide)17$11,882
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen299$8,103
Advair HfaFluticasone Propion/Salmeterol18$7,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$221$349,143271 claims
Lilly USA, LLCMounjaro$88$220,759186 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$46$97,08793 claims
Boehringer IngelheimJardiance, Spiriva Respimat$172$62,65271 claims
NovartisEntresto$136$14,74820 claims
MerckJanumet, Belsomra$66$11,63424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Grants

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →